Disopyramide
Treatment for Hypertrophic Cardiomyopathy
Typical Dosage: 100-200mg three to four times daily
Effectiveness
75%
Safety Score
58%
Clinical Trials
4
Participants
2K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
58
DangerousModerateSafe
Treatment Details
Dosage Range
100-200mg three to four times daily
Time to Effect
Days to weeks
Treatment Duration
Lifetime
Evidence Quality
MODERATE-HIGHNumber Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$700
Monitoring:$1,000
Side Effect Mgmt:$200
Total Annual:$1,900
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODQALYs Gained
7
Outcome-Based Costs
Cost per Responder
$2,714
Disopyramide Outcomes
for Hypertrophic Cardiomyopathy
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+70%
Common Side Effects
Dry mouth
+35%
Blurred vision
+15%
Urinary retention
+10%
Constipation
+15%
QT prolongation/Proarrhythmia
+8%
Hypoglycemia
+1%
Active Clinical Trials
1 active trial recruiting for Disopyramide in Hypertrophic Cardiomyopathy
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
NCT05489705RECRUITING
1.6K participants
OBSERVATIONAL
Anchorage, United States +98 more
Started: Aug 16, 2022
Completed Clinical Trials
1 completed trial for Disopyramide in Hypertrophic Cardiomyopathy
Dose-finding Study to Evaluate the Safety, Tolerability, PK, and PD of CK-3773274 in Adults With HCM
NCT04219826COMPLETEDPHASE2
96 participants
INTERVENTIONAL
Los Angeles, United States +21 more
Started: Jan 10, 2020